Literature DB >> 1392258

Spinal fractures during fluoride therapy for osteoporosis: relationship to spinal bone density.

S M Farley1, J E Wergedal, J R Farley, G N Javier, E E Schulz, J R Talbot, C R Libanati, L Lindegren, M Bock, M M Goette.   

Abstract

Recent studies report that fluoride therapy for osteoporosis increases spinal bone density without improving vertebral fracture rate, challenging the notion that restoration of bone mass improves bone fragility. To further evaluate this issue, the relationship between spinal bone density and vertebral fracture rate was examined in a large number of fluoride-treated, osteoporotic patients. A retrospective assessment was made of clinical data collected from our observations of 389 osteoporotics treated with fluoride 30 +/- 8 mg/day (mean +/- SD) (equivalent to 66 +/- 17 mg NaF/day) and calcium 1500 mg/day for 28 +/- 18 months. Fracture rate and bone density were assessed in the same region of the spine (i.e., T12 through L4) using quantitative computed tomography (QCT). Spinal bone density increased with time on fluoride, but the relationship was hyperbolic (r = 0.99, p less than 0.0001; asymptote = 167 mg/cc on double-reciprocal plot), suggesting a plateau in the response. The spinal fracture rate decreased as a function of time on therapy (r = -0.83, p less than 0.01), and was inversely related to spinal bone density during fluoride therapy (r = 0.70, p less than 0.001 on arithmetic plot; r = -0.79, p less than 0.001 on semi-log plot). The subgroup of patients who responded to treatment with a significant increase in spinal bone density had a 48% reduction in spinal fracture rate compared with non-responders (p less than 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1392258     DOI: 10.1007/bf01624143

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  16 in total

1.  Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.

Authors:  T Storm; G Thamsborg; T Steiniche; H K Genant; O H Sørensen
Journal:  N Engl J Med       Date:  1990-05-03       Impact factor: 91.245

2.  Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures.

Authors:  C Y Pak; K Sakhaee; J E Zerwekh; C Parcel; R Peterson; K Johnson
Journal:  J Clin Endocrinol Metab       Date:  1989-01       Impact factor: 5.958

3.  Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.

Authors:  B L Riggs; S F Hodgson; W M O'Fallon; E Y Chao; H W Wahner; J M Muhs; S L Cedel; L J Melton
Journal:  N Engl J Med       Date:  1990-03-22       Impact factor: 91.245

4.  Treatment of osteoporosis with fluoride, calcium, and vitamin D.

Authors:  D Briancon; P J Meunier
Journal:  Orthop Clin North Am       Date:  1981-07       Impact factor: 2.472

5.  The effect of fluoride and calcium on spinal bone mineral content: a controlled, prospective (3 years) study.

Authors:  T Hansson; B Roos
Journal:  Calcif Tissue Int       Date:  1987-06       Impact factor: 4.333

6.  Treatment of the vertebral crush fracture syndrome with enteric-coated sodium fluoride tablets and calcium supplements.

Authors:  C Nagant de Deuxchaisnes; J P Devogelaer; G Depresseux; J Malghem; B Maldague
Journal:  J Bone Miner Res       Date:  1990-03       Impact factor: 6.741

7.  Treatment of primary osteoporosis with fluoride and calcium. Clinical tolerance and fracture occurrence.

Authors:  B L Riggs; S F Hodgson; D L Hoffman; P J Kelly; K A Johnson; D Taves
Journal:  JAMA       Date:  1980-02-01       Impact factor: 56.272

8.  Incorporation of sodium fluoride into cortical bone does not impair the mechanical properties of the appendicular skeleton in rats.

Authors:  T A Einhorn; G K Wakley; S Linkhart; E B Rush; S Maloney; E Faierman; D J Baylink
Journal:  Calcif Tissue Int       Date:  1992-08       Impact factor: 4.333

9.  Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy.

Authors:  B L Riggs; E Seeman; S F Hodgson; D R Taves; W M O'Fallon
Journal:  N Engl J Med       Date:  1982-02-25       Impact factor: 91.245

10.  Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis.

Authors:  N Mamelle; P J Meunier; R Dusan; M Guillaume; J L Martin; A Gaucher; A Prost; G Zeigler; P Netter
Journal:  Lancet       Date:  1988-08-13       Impact factor: 79.321

View more
  12 in total

1.  What is the future for fluoride in the treatment of osteoporosis?

Authors:  J D Ringe; P J Meunier
Journal:  Osteoporos Int       Date:  1995-03       Impact factor: 4.507

2.  The increase in spinal bone density that occurs in response to fluoride therapy for osteoporosis is not maintained after the therapy is discontinued.

Authors:  J R Talbot; M M Fischer; S M Farley; C Libanati; J Farley; A Tabuenca; D J Baylink
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

Review 3.  Hormone replacement therapy: II. A pharmacoeconomic appraisal of its role in the prevention of postmenopausal osteoporosis and ischaemic heart disease.

Authors:  R Whittington; D Faulds
Journal:  Pharmacoeconomics       Date:  1994-06       Impact factor: 4.981

4.  Serum fluoride and serum osteocalcin levels in response to a novel sustained-release monofluorophosphate preparation: comparison with plain monofluorophosphate.

Authors:  A Battmann; H Resch; C R Libanati; D Ludy; M Fischer; S Farley; D J Baylink
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

5.  On fluoride and bone strength.

Authors:  D J Baylink; J E Wergedal; J R Farley; T A Einhorn
Journal:  Calcif Tissue Int       Date:  1995-05       Impact factor: 4.333

6.  Pharmacokinetic profile of a new fluoride preparation: sustained-release monofluorophosphate.

Authors:  H Resch; C Libanati; J Talbot; M Tabuenca; S Farley; P Bettica; W Tritthart; D Baylink
Journal:  Calcif Tissue Int       Date:  1994-01       Impact factor: 4.333

7.  In corticosteroid-treated respiratory diseases, monofluorophosphate increases lumbar bone density: a double-masked randomized study.

Authors:  G Guaydier-Souquières; P O Kotzki; J P Sabatier; B Basse-Cathalinat; G Loeb
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

8.  Monofluorophosphate increases lumbar bone density in osteopenic patients: a double-masked randomized study.

Authors:  J L Sebert; P Richard; I Mennecier; J P Bisset; G Loeb
Journal:  Osteoporos Int       Date:  1995-03       Impact factor: 4.507

9.  Spine and femur BMD by DXA in patients with varying severity spinal osteoporosis.

Authors:  P J Ryan; G M Blake; R Herd; J Parker; I Fogelman
Journal:  Calcif Tissue Int       Date:  1993-04       Impact factor: 4.333

10.  Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. A one-year study.

Authors:  M H Lafage; R Balena; M A Battle; M Shea; J G Seedor; H Klein; W C Hayes; G A Rodan
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.